Biophan Technologies, Inc. Rated 'Outperform,' Target $5.17 by Investrend Affiliate Beacon Equity Research.

NEW YORK -- (Investrend Research Syndicate) Biophan Technologies, Inc. (OTCBB: BIPH) has been rated "Outperform," with a price target of $5.17 by Investrend Research affiliate Beacon Equity Research. The report is authored by Senior Research Analyst, Shailesh Dhuri.

E[acute accent]The full report is available at http://www.beaconequityresearch.com and http://www.investrendresearch.com

E[acute accent]In the report, Mr. Dhuri writes, "Biophan Technologies, Inc. (OTCBB: BIPH) is an emerging biomedical technology company that provides solutions for making biomedical devices safe for use with the Magnetic Resonance Imaging (MRI) diagnostic procedure. Biophan has strong growth prospects in this growing market as it already has accumulated an impressive portfolio of 114 patents; which include 34 issued, 8 allowed, and 72 applications in process. Biophan's patent portfolio covers areas that include nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics. E[acute accent]MRI is considered one of the most important medical diagnostic tools available today... However, a serious drawback to MRI technology is that it cannot be safely used on patients with pacemakers or other biomedical implants. This is due to the fact that these devices (such as pacemakers and cardioverter/defibrillator/pacemakers) are sensitive to a variety of forms of electromagnetic interference (EMI). These devices contain sensing and logic systems that respond to low-level electrical signals that come from the targeted tissue region of the patient. E[acute accent]Our detailed valuation exercise has led to three different values for the firm, under three market conditions. Under our "Average Conditions" assumptions, we arrive at a target share price of $5.20. Under "Optimistic Conditions," the target share price comes to $13.70. Under "Pessimistic Conditions," the target price works out to $0.80. Overall, by using a weighted-average of the three scenarios, we arrive at a price target of $5.17.

E[acute accent]Beacon Equity Research, LLC is a fee-based, comprehensive investment research firm, focusing primarily on the underserved small-cap sector. All Beacon analysts are seasoned industry professionals and adhere to the CFA Institute's (CFAI) stringent ethics and standards of practice guidelines. Beacon Research does not have any investment banking relationships with any of the companies covered. All analysts are compensated prior to performing their investment research and are not compensated in any way based on the future performance of the equities they follow. E[acute accent]Both Beacon Equity Research and Investrend subscribe to the "Standards for Independent Research Providers" at http://www.firstresearchconsortium.com. Beacon Research Partners has been compensated $18,000 by Biophan Technologies, Inc. for one year of enrollment in its research program. E[acute accent]Complete information is available at the company's InvestorPower page at http://www.investrend.com/company/list.asp?sPathParam=yes. Investors are advised to read disclosures carefully before trading in the equities of any enrolled company. E[acute accent]Anyone interested in receiving alerts regarding Biophan research should email [e-mail] with "BIPH" in the subject line.